Expression of sarcosine metabolism-related proteins according to metastatic site in breast cancer

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 11, 2014, Pages 7824-7833

  Cha, Yoon Jin ^a   Kim, Do Hee ^a   Jung, Woo Hee ^a   Koo, Ja Seung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Breast cancer; Metabolism; Molecular subtype; Sarcosine

Indexed keywords

GLYCINE METHYLTRANSFERASE; GNMT PROTEIN, HUMAN; PIPOX PROTEIN, HUMAN; SARCOSINE DEHYDROGENASE; SARCOSINE OXIDASE;

ANTIBODY SPECIFICITY; BONE TUMOR; BRAIN TUMOR; BREAST TUMOR; FEMALE; HUMAN; LIVER TUMOR; LUNG TUMOR; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; SECONDARY;

BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GLYCINE N-METHYLTRANSFERASE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; ORGAN SPECIFICITY; SARCOSINE DEHYDROGENASE; SARCOSINE OXIDASE;

EID: 84919478853     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Weil RJ, Palmieri DC, Bronder JL, Stark AM and Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol 2005; 167: 913-920.
2. Woodhouse EC, Chuaqui RF and Liotta LA. General mechanisms of metastasis. Cancer 1997; 80: 1529-1537.
3. Abali H and Celik I. High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel. Am J Clin Oncol 2002; 25: 632-633.
4. Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thurlimann B, Price KN, Castiglione-Gertsch M, Coates AS, Lindtner J, Collins J, Senn HJ, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M and Rudenstam CM. Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 2000; 18: 3925-3935.
5. Evans AJ, James JJ, Cornford EJ, Chan SY, Burrell HC, Pinder SE, Gutteridge E, Robertson JF, Hornbuckle J and Cheung KL. Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol (R Coll Radiol) 2004; 16: 345-349.
6. Gaedcke J, Traub F, Milde S, Wilkens L, Stan A, Ostertag H, Christgen M, von Wasielewski R and Kreipe HH. Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Mod Pathol 2007; 20: 864-870.
7. Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, Crowe JP, Choueiri TK, Dawson AE, Budd GT, Tubbs RR, Casey G and Weil RJ. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006; 30: 1097-1104.
8. Lorincz T, Toth J, Badalian G, Timar J and Szendroi M. HER-2/neu genotype of breast cancer may change in bone metastasis. Pathol Oncol Res 2006; 12: 149-152.
9. Nicolson GL. Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 1988; 7: 143-188.
10. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1: 571-572.
11. Hasebe T, Imoto S, Yokose T, Ishii G, Iwasaki M and Wada N. Histopathologic factors significantly associated with initial organ-specific metastasis by invasive ductal carcinoma of the breast: a prospective study. Hum Pathol 2008; 39: 681-693.
12. Wei B, Wang J, Bourne P, Yang Q, Hicks D, Bu H and Tang P. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas. Hum Pathol 2008; 39: 1809-1815.
13. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C and Chinnaiyan AM. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 910-914.
14. Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, Mehra R, Siddiqui J, Palapattu G, Wei JT, Michailidis G, Sreekumar A and Chinnaiyan AM. The role of sarcosine metabolism in prostate cancer progression. Neoplasia 2013; 15: 491-501.
15. Baum CE, Price DK and Figg WD. Sarcosine as a potential prostate cancer biomarker and therapeutic target. Cancer Biol Ther 2010; 9: 341-342.
16. Lucarelli G, Ditonno P, Bettocchi C, Spilotros M, Rutigliano M, Vavallo A, Galleggiante V, Fanelli M, Larocca AM, Germinario CA, Maiorano E, Selvaggi FP and Battaglia M. Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer. Future Oncol 2013; 9: 899-907.
17. Elston CW and Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
18. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL and Wolff AC. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
19. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM and Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
20. Won KY, Kim GY, Kim YW, Song JY and Lim SJ. Clinicopathologic correlation of beclin-1 and bcl-2 expression in human breast cancer. Hum Pathol 2010; 41: 107-112.
21. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B and Senn HJ. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
22. Yoon JK, Kim do H and Koo JS. Implications of differences in expression of sarcosine metabolism-related proteins according to the molecular subtype of breast cancer. J Transl Med 2014; 12: 149.